NOWDiagnostics
NOWDiagnostics develops and manufactures FDA-authorized over-the-counter and point-of-care rapid diagnostic tests using its proprietary Touch to Test platform, serving U.S. consumers, healthcare providers, and public health programs across retail, Labcorp professional, and TakeMeHome channels.
- Company typePrivate
- Founded2013
- HeadquartersSpringdale, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What NOWDiagnostics does
NOWDiagnostics, Inc. (NOWDx) is a Springdale, Arkansas-based developer and manufacturer of over-the-counter (OTC) and point-of-care (POC) rapid diagnostic tests, founded in 2013. The company's core offering is its proprietary "Touch to Test" platform — a patented buffer-less lateral flow architecture with sophisticated plasma separation microfluidics that enables virtually any immunological assay to be performed in a single step using a tiny amount of capillary blood or saliva, yielding results in minutes without buffers, reagents, or additional equipment. The platform is protected by 75+ issued and pending patents and supports a pipeline of 30+ tests. NOWDx markets two principal product lines: the First To Know consumer brand (anchored by the FDA De Novo authorized OTC syphilis test, the first and only rapid in-home syphilis test in the U.S., launched nationally in November 2024) and the ADEXUSDx professional brand (FDA-cleared hCG pregnancy test, COVID-19 antibody test under EUA, and CE-marked syphilis test), plus the Direct Collect sample collection device and acquired CELLMIC smartphone reader technology.
NOWDx monetizes primarily through one-time unit sales of diagnostic tests across three channels: (1) OTC consumer distribution via Amazon and 15,000+ retail pharmacy and drugstore locations nationwide, with First To Know Syphilis priced under $30; (2) professional and hospital distribution through an exclusive U.S. partnership with Labcorp (which is also a Series B co-investor), with ADEXUSDx hCG priced at $150 per unit and Labcorp OnDemand availability planned for 2025; and (3) public health distribution via the NASTAD/BHOC TakeMeHome initiative providing free tests to at-risk consumers. International distribution is handled through 14 distributors across 10 countries, leveraging CE Mark approvals. Manufacturing is conducted in a fully automated Springdale facility with 2 million tests per month capacity built in partnership with Kinematic. Ownership is held by venture investors including DigitalDx Ventures (Series B lead), Labcorp Venture Fund, Kompass Kapital Management, and BARDA (federal grant), with operating leadership recruited substantially from former OraSure Technologies executives, including CEO Lisa Nibauer (appointed May 2026), Board Chair Dr. Stephen Tang, CSO Dr. Jody Berry, and VP Sales Todd Grice.
NOWDiagnostics firmographics
Firmographics- Name
- NOWDiagnostics
- Legal name
- NOWDiagnostics, Inc.
- Website
- https://nowdx.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NOWDiagnostics develops and manufactures FDA-authorized over-the-counter and point-of-care rapid diagnostic tests using its proprietary Touch to Test platform, serving U.S. consumers, healthcare providers, and public health programs across retail, Labcorp professional, and TakeMeHome channels.
- Ownership category
- akta.pro rank
NOWDiagnostics industry classification
Industry- Product category
- Rapid Diagnostic Tests
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Home-Use & OTC Rapid Self-Tests (Consumer POCT kits) (HLAHAOAK)
- akta.pro secondary industries
- Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection) (HLAHAOAF), Home Diagnostic & Self-Test OTC Kits (HLAIADAO)
Keywords
Where NOWDiagnostics is headquartered
LocationHeadquarters
- HQ city
- Springdale
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
NOWDiagnostics business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Test Sales: One-time sale of rapid diagnostic tests including First To Know Syphilis Test and ADEXUSDx hCG Test through retail, pharmacy, online channels, and professional healthcare settings.
- Professional Distribution Revenue: Revenue from Labcorp exclusive distribution partnership for First To Know Syphilis Test in professional and hospital settings.
- OTC Consumer Sales: Direct-to-consumer sales of OTC tests through Amazon and retail pharmacy chains across 15,000+ locations nationwide.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | First To Know Syphilis Test - OTC retail pricing |
| Unit Pricing | Pay-as-you-go | ADEXUSDx hCG Test - Professional use |
Go-to-market motion5 records
Distribution channels5 records
Marketing channels5 records
NOWDiagnostics product offering
Product offeringCore offering
NOWDiagnostics develops and manufactures patented "Touch to Test" over-the-counter and point-of-care diagnostic tests that use a single drop of capillary blood or saliva and deliver results in minutes without buffers, reagents, or additional equipment. The company's commercial product lines include the First To Know OTC Syphilis Test (FDA De Novo authorized), the ADEXUSDx hCG professional pregnancy test (FDA 510(k) cleared), the ADEXUSDx COVID-19 Antibody Test (FDA EUA), and the CE Marked ADEXUSDx Syphilis rapid test, with 30+ additional tests in its development pipeline.
Product overview
NOWDiagnostics (NOWDx) is a diagnostic test manufacturer offering two main product lines: First To Know (OTC consumer tests) and ADEXUSDx (professional/POC tests). The core offering is the proprietary Touch to Test technology platform, enabling one-step immunological assays using capillary blood or saliva with results in minutes. The flagship consumer product is the First To Know Syphilis Test (FDA-authorized OTC, August 2024), the only in-home syphilis test in the U.S. The ADEXUSDx line includes the FDA-cleared hCG pregnancy test, COVID-19 antibody test (EUA), and syphilis rapid test (CE Mark). Supporting products include Direct Collect sample collection device and CELLMIC smartphone readers (acquired technology). With 30+ tests in pipeline and 75+ patents, the company serves markets worldwide from its Springdale, Arkansas headquarters.
Differentiator
Problem solved
Functional benefit
Brands
- First To Know®: Over-the-counter diagnostic test brand including the FDA-authorized First To Know Syphilis Test and First To Know Pregnancy Test (EU).
- ADEXUSDx®
Products and services
- First To Know Syphilis Test Over-the-counter rapid syphilis test delivering in-home results in 15 minutes from a single drop of capillary blood; detects Treponema pallidum antibodies using a patented buffer-less lateral flow device with 93.4% PPA and 99.5% NPA in a 1,270-person clinical study. Sold to consumers via Amazon, retail pharmacies, and the NASTAD/BHOC TakeMeHome initiative.
- ADEXUSDx hCG Test FDA 510(k)-cleared professional-use immunoassay for qualitative detection of human chorionic gonadotropin (hCG) in whole blood, plasma, or serum; delivers results in 10 minutes from a single fingerstick drop with 99% sensitivity and specificity, no reagents or equipment required. Used by clinicians for early pregnancy detection, including in hospital settings via the Labcorp distribution partnership.
- First To Know Pregnancy Test (EU) Blood-based pregnancy test for the European market that detects pregnancy earlier than urine-based tests; sold OTC in Europe following EC approval.
- ADEXUSDx COVID-19 Antibody Test Self-contained rapid serology assay measuring SARS-CoV-2 antibodies (IgA, IgG, IgM); delivers results in 15 minutes from a single drop of fingerstick blood with no buffers, reagents, or additional equipment required; FDA EUA authorized for point-of-care use and CE Marked.
Quantifiable outcome
- 93.4% positive percent agreement (PPA) and 99.5% negative percent agreement (NPA) in clinical study of 1,270 people for First To Know Syphilis Test
- +3 more outcomes
Companies that use NOWDiagnostics
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles3 records
NOWDiagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
NOWDiagnostics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major and core.
- NASTAD (National Alliance of State and Territorial AIDS Directors)majorCollaboration through TakeMeHome initiative to address growing syphilis epidemic by expanding access to in-home testing. NASTAD provides public health expertise and program infrastructure for free test distribution.
- BHOC (Building Healthy Online Communities)majorTakeMeHome initiative partner with ability to engage communities through digital platforms. Provides discreet and easy-to-use testing kits with educational resources.
- LabcorpcoreExclusive U.S. distributor of First To Know Syphilis Test in professional and hospital settings. Labcorp to offer test through extensive distribution network and Labcorp OnDemand in 2025. Also U.S. distribution partner for ADEXUSDx hCG test in hospital settings.
Scale indicators12 records
Recent moves8 records
Expansion highlights7 records
NOWDiagnostics competitors and assessment
Company assessmentDirect peers
- OraSure Technologies: Developer of rapid diagnostic tests including the OraQuick HIV, HCV and Ebola tests. Most direct comparable in rapid immunoassay/OTC diagnostics, and currently litigation counterpart of NOWDx. Both companies target decentralized testing for infectious disease with similar lateral-flow technology.
- Chembio Diagnostics: Specialty rapid point-of-care diagnostics company focused on infectious disease detection (HIV, syphilis, COVID-19, Zika). Highly comparable in product mix (rapid immunodiagnostics for STI and infectious disease), regulatory pathway, and target customers (clinics, public health, OTC).
- Trinity Biotech: Developer and manufacturer of diagnostic tests for infectious disease, HbA1c, and other analytes using both lab-based and rapid/point-of-care formats. Comparable in target customers (clinical labs, public health) and syphilis/HIV test focus.
Broad incumbents
- Bio-Rad Laboratories: Manufacturer of clinical diagnostics including rapid test platforms and quality controls for clinical labs. Overlaps with NOWDx in IVD test manufacturing and clinical diagnostic workflows.
- Hologic: Women's health and diagnostics leader (Aptima, Panther) with growing rapid-test footprint. Adjacent in women's health and STI testing categories where NOWDx's hCG and syphilis tests compete.
- Becton Dickinson (BD): Major medical technology company with a large diagnostics segment including rapid molecular and immunoassay tests (e.g., BD Veritor). Provides both competition and potential partnership context for NOWDx's POC ambitions.
- Sekisui Diagnostics: Global diagnostics company offering rapid test systems (e.g., OSOM) for infectious disease and women's health including hCG. Comparable product mix and channels (OTC, professional) to NOWDx's ADEXUSDx and First To Know lines.
- QuidelOrtho: Large diagnostics manufacturer offering rapid immunoassays (QuickVue), Sofia platform, and a broad portfolio of clinical diagnostics and OTC tests. Overlap with NOWDx in point-of-care and OTC infectious-disease testing at much larger scale.
- Abbott Diagnostics: Global diagnostics giant producing rapid tests such as Binax and the Panbio COVID-19 test, plus extensive POC and OTC offerings. Comparable technology architecture and end markets; far larger scale and distribution.
Emerging players
- Lucira Health (Pfizer): At-home molecular diagnostic test platform (COVID-19, Flu) positioned at the OTC/at-home intersection. Represents the emerging class of OTC molecular diagnostics that NOWDx aims to enter with its planned Strep Throat test.
Market position
Competitive moat6 records
Key highlights7 records
Customer concentration
NOWDiagnostics social profiles
Digital presenceNOWDiagnostics compliance and trust
Trust signalCompliance7 records
NOWDiagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
NOWDiagnostics leadership team
Management profileNumber of profiles
Profiles6 records
NOWDiagnostics subsidiaries and ownership
Company hierarchySubsidiaries2 records
NOWDiagnostics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NOWDiagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NOWDiagnostics
What does NOWDiagnostics do?
NOWDiagnostics develops and manufactures patented "Touch to Test" over-the-counter and point-of-care diagnostic tests that use a single drop of capillary blood or saliva and deliver results in minutes without buffers, reagents, or additional equipment. The company's commercial product lines include the First To Know OTC Syphilis Test (FDA De Novo authorized), the ADEXUSDx hCG professional pregnancy test (FDA 510(k) cleared), the ADEXUSDx COVID-19 Antibody Test (FDA EUA), and the CE Marked ADEXUSDx Syphilis rapid test, with 30+ additional tests in its development pipeline.
Is NOWDiagnostics a public or private company?
NOWDiagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was NOWDiagnostics founded?
NOWDiagnostics was founded in 2013. It employs 11 to 50 people.
Where is NOWDiagnostics based?
NOWDiagnostics is headquartered in Springdale, United States, in the North America region.
How does NOWDiagnostics make money?
Three revenue lines are on record. Diagnostic Test Sales are the primary driver. The others are professional Distribution Revenue and OTC Consumer Sales.
Who are NOWDiagnostics's main competitors?
Direct peers on record are OraSure Technologies, Chembio Diagnostics and Trinity Biotech. Broad incumbents are Bio-Rad Laboratories, Hologic, Becton Dickinson (BD), Sekisui Diagnostics, QuidelOrtho and Abbott Diagnostics. Lucira Health (Pfizer) is listed as an emerging player.
Does NOWDiagnostics have an API?
No public API is recorded for NOWDiagnostics.
What industry is NOWDiagnostics in?
NOWDiagnostics's product category is Rapid Diagnostic Tests. Its primary akta.pro industry code is HLAHAOAK, Home-Use & OTC Rapid Self-Tests (Consumer POCT kits), with a secondary code of HLAHAOAF, Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection). Its NAICS code is 325413 and its SIC code is 3841.